Opendata, web and dolomites

MIN4ALD SIGNED

Use of MIN-102 for the treatment of children with cerebral ALD

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MIN4ALD project word cloud

Explore the words cloud of the MIN4ALD project. It provides you a very rough idea of what is the project "MIN4ALD" about.

visual    investors    genetic    demonstration    huge    paediatric    alternative    drug    motor    period    usually    symptoms       boy    expand    grow    impressive    excellent    onset    global    treatment    us    ald    diseases    reference    orphan    patent    therapy    rare    disorder    candidate    nervous    received    internationally    billion    disease    stem    cognitive    hematopoietic    auditory    min    occurring    time    pharmacological    pharmaceutical    progressive    childhood    leaders    fatal    optimal    linked    nerve    fda    central    min4ald    amount    brain    designation    procedure    102    devastating    aggressive    company    raised    pharma    indicated    consolidation    transplantation    treat    opinion    phenotype    cagr    2022    minoryx    patients       holds    niche    feasibility    cell    2015    function    business    suppose    death    cerebral    always    itself    576    valued    24    market    121    opportunity    stimulus    cald    cells    adrenoleukodystrophy    demonstrated   

Project "MIN4ALD" data sheet

The following table provides information about the project.

Coordinator
MINORYX THERAPEUTICS S.L. 

Organization address
address: AVENIDA ERNEST LLUCH 32, TCM3, TECNOCAMPUS MATARO
city: MATARO BARCELONA
postcode: 8302
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 4˙437˙500 €
 EC max contribution 3˙106˙250 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MINORYX THERAPEUTICS S.L. ES (MATARO BARCELONA) coordinator 3˙106˙250.00

Map

 Project objective

The objective of the MIN4ALD project is the development of a new pharmacological therapy to treat paediatric patients with cerebral ALD (cALD) - the most rapidly progressive and devastating phenotype of X-ALD (X-linked adrenoleukodystrophy).

cALD is a rare, fatal genetic disorder that affects nerve cells in the brain. Symptoms of cALD usually occur in a boy’s early childhood, and are characterized by rapidly progressive loss of visual, auditory, motor and cognitive function, with death usually occurring after 2 to 4 years from disease onset.

Currently, there is no pharmacological treatment available on the market. The only existing alternative for cALD patients is hematopoietic stem cell transplantation, yet the procedure itself is very aggressive and results are not always optimal.

Minoryx has developed a candidate drug that has demonstrated in several studies an excellent potential to treat patients with X-ALD. MIN4ALD Phase 2 demonstration is key to bring this unique treatment to the market. The results obtained in the Feasibility Analysis carried out indicated that MIN4ALD could be a huge business opportunity within the orphan diseases market.

The Global orphan diseases market is a niche market valued at US$ 121.6 billion in 2015. It is expected to grow to US$ 576.9 billion by 2022, with an average CAGR of 24.9% during the period 2015-2022. This is an impressive growth compared to the Global pharma market, which projects a 6.3% CAGR through 2022.

Minoryx has raised an important funding amount for R&D development from leading investors and has the support of reference Key Opinion Leaders. Minoryx received Orphan Drug Designation from both EU and FDA and holds a patent application covering the use of MIN-102 for X-ALD and other diseases affecting the central nervous system.

MIN4ALD will suppose a crucial stimulus for Minoryx to expand internationally and improve time-to-market, leading to the consolidation of the company in the pharmaceutical market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIN4ALD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIN4ALD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More